Monday, February 3, 2025
HomeFunding CA-based Carlsmed Secures $52.5Million in Series C Round Funding

[Funding alert] CA-based Carlsmed Secures $52.5Million in Series C Round Funding

Carlsmed, an AI-enabled personalized surgery Medtech company secures $52.5million in series C round funding. This round was co-led by B Capital and U.S. Venture Partners.

Carlsmed, an AI-enabled personalized surgery Medtech company secures $52.5million in series C round funding. This round was co-led by B Capital and U.S. Venture Partners.

These proceeds will be used to accelerate the commercialization of the aprevoĀ® personalized spine surgery platform for lumbar fusion procedures and the development of aprevoĀ® for cervical fusions, which will launch in 2025.

Read also – NYC-based BigID Secures $60Million in Growth Funding

Mike Cordonnier, CEO of Carlsmed said, ā€œWe started Carlsmed to improve patient outcomes through personalized surgery, and recent clinical publications indicate that aprevoĀ® patient specific implants are achieving this goal, Our AI-enabled technology platform and innovative business model allows us to scale production rapidly to meet growing demand and empower patients.ā€

Dr. Robert Mittendorff, General Partner and Head of Healthcare at B Capital, said, ā€œIt is transforming spine surgery through the application of its AI-enabled technology and has proven to be a category creator in a market overdue for meaningful innovation. Personalized surgery will be the standard of care in spine, and we look forward to supporting this transformation led by Carlsmed.ā€

It has received Breakthrough Device designation by the FDA for aprevoĀ® lumbar and cervical patient-specific interbody fusion devices. It’s implantable devices and software platforms are FDA cleared for lumbar spine fusion, including anterior, lateral, and transforaminal approaches.

About Carlsmed

Carlsmed creates customized aprevoĀ® spine fusion devices and the best surgical strategies for each patient using patient data and exclusive digital technology. Commercially available in the United States, the CarlsmedĀ® aprevoĀ® devices have received FDA clearance and FDA Breakthrough Designation, an unprecedented honor for any implanted device in the industry.

Read also – CA-based Superlinked Secures $9.5Million in Seed Funding

It’s mission is to improve outcomes and decrease the cost of healthcare for spine surgery. The aprevoĀ® personalized surgery platform is designed to advance the standard of care for spine surgery one patient at a time.

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular